tiprankstipranks
Royalty Pharma Bets Big on Voranigo’s Market Success
Company Announcements

Royalty Pharma Bets Big on Voranigo’s Market Success

Don't Miss our Black Friday Offers:

Royalty Pharma (RPRX) just unveiled an update.

Servier’s new drug Voranigo has gained FDA approval, promising treatment for patients with a specific type of brain cancer. Under a lucrative deal, Royalty Pharma will pay Agios $905 million for a slice of Voranigo’s future sales, betting on the drug’s success with projected annual sales exceeding $1 billion and generating substantial royalties possibly until 2038. This deal underscores the high stakes and potential rewards in pharmaceutical investments.

For an in-depth examination of RPRX stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyRoyalty Pharma price target raised to $39 from $38 at BofA
Gilan Miller-GertzEx-Dividend Date Nearing for These 10 Stocks – Week of November 11, 2024
TheFlyBiotech Alert: Searches spiking for these stocks today
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App